Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.74 USD
−235.93 M USD
0.00 USD
54.91 M
About Neumora Therapeutics, Inc.
Sector
CEO
Henry O. Gosebruch
Headquarters
Watertown
Website
Founded
2019
FIGI
BBG012W9C4X1
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NMRA is 13.54 USD — it has increased by 2.44% in the past 24 hours. Watch Neumora Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neumora Therapeutics, Inc. stocks are traded under the ticker NMRA.
NMRA stock has risen by 6.90% compared to the previous week, the month change is a −10.58% fall, over the last year Neumora Therapeutics, Inc. has showed a 27.38% increase.
We've gathered analysts' opinions on Neumora Therapeutics, Inc. future price: according to them, NMRA price has a max estimate of 30.00 USD and a min estimate of 15.00 USD. Watch NMRA chart and read a more detailed Neumora Therapeutics, Inc. stock forecast: see what analysts think of Neumora Therapeutics, Inc. and suggest that you do with its stocks.
NMRA reached its all-time high on Mar 8, 2024 with the price of 21.00 USD, and its all-time low was 8.33 USD and was reached on Jun 26, 2024. View more price dynamics on NMRA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NMRA stock is 4.46% volatile and has beta coefficient of 2.13. Track Neumora Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neumora Therapeutics, Inc. there?
Today Neumora Therapeutics, Inc. has the market capitalization of 2.08 B, it has decreased by −6.08% over the last week.
Yes, you can track Neumora Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Neumora Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
NMRA earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.37 USD resulting in a 0.54% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Neumora Therapeutics, Inc. earnings.
Neumora Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NMRA net income for the last quarter is −58.70 M USD, while the quarter before that showed −53.72 M USD of net income which accounts for −9.27% change. Track more Neumora Therapeutics, Inc. financial stats to get the full picture.
No, NMRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 124.00 employees. See our rating of the largest employees — is Neumora Therapeutics, Inc. on this list?
Like other stocks, NMRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neumora Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neumora Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neumora Therapeutics, Inc. stock shows the strong buy signal. See more of Neumora Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.